| 2012 | A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. | GYNECOLOGIC ONCOLOGY |
| 2022 | A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
| GYNECOLOGIC ONCOLOGY |
| 2017 | BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients | GYNECOLOGIC ONCOLOGY |
| 2020 | CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer | GYNECOLOGIC ONCOLOGY |
| 2022 | Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer | GYNECOLOGIC ONCOLOGY |
| 2002 | Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma | GYNECOLOGIC ONCOLOGY |
| 2015 | De-escalation of the cumulative central radiation dose according to the tumor response can reduce rectal toxicity without compromising the treatment outcome in patients with uterine cervical cancer | GYNECOLOGIC ONCOLOGY |
| 2010 | Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI | GYNECOLOGIC ONCOLOGY |
| 2016 | Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women | GYNECOLOGIC ONCOLOGY |
| 2007 | Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy | GYNECOLOGIC ONCOLOGY |
| 1996 | Expression of epidermal growth factor receptor in carcinoma of the cervix | GYNECOLOGIC ONCOLOGY |
| 2018 | Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer | GYNECOLOGIC ONCOLOGY |
| 2009 | Functional polymorphism in manganese superoxide dismutase and antioxidant status: their interactions on the risk of cervical intraepithelial neoplasia and cervical cancer. | GYNECOLOGIC ONCOLOGY |
| 2003 | G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value | GYNECOLOGIC ONCOLOGY |
| 2005 | Germline Mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma | GYNECOLOGIC ONCOLOGY |
| 2018 | Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. | GYNECOLOGIC ONCOLOGY |
| 2022 | Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study | GYNECOLOGIC ONCOLOGY |
| 2021 | Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee | GYNECOLOGIC ONCOLOGY |
| 2022 | Long term oncologic and reproductive outcomes after robot-assisted radical trachelectomy for early-stage cervical cancer. An international multicenter study
| GYNECOLOGIC ONCOLOGY |
| 2021 | Markedly increased risk of malignancies in women with endometriosis | GYNECOLOGIC ONCOLOGY |
| 2004 | Minimal change disease in a patient with ovarian papillary serous carcinoma | GYNECOLOGIC ONCOLOGY |
| 2003 | Osteopontin is down-regulated in hydatidiform mole | GYNECOLOGIC ONCOLOGY |
| 2019 | Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
| GYNECOLOGIC ONCOLOGY |
| 2003 | Pelvic leiomyomatosis with intracaval and intracardiac extension: a case report and review of the literature | GYNECOLOGIC ONCOLOGY |
| 2018 | Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer | GYNECOLOGIC ONCOLOGY |
| 2011 | Prospective evaluation of longitudinal changes in human papillomavirus genotype and phylogenetic clade associated with cervical disease progression. | GYNECOLOGIC ONCOLOGY |
| 2019 | Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041) | GYNECOLOGIC ONCOLOGY |
| 2022 | Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea | GYNECOLOGIC ONCOLOGY |
| 2008 | Robotic radical hysterectomy with pelvic lymphadenectomy for cervical carcinoma: a pilot study | GYNECOLOGIC ONCOLOGY |
| 2022 | Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study | GYNECOLOGIC ONCOLOGY |
| 2007 | The expressions of the Rb pathway in cervical intraepithelial neoplasia; predictive and prognostic significance | GYNECOLOGIC ONCOLOGY |
| 2011 | The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer | GYNECOLOGIC ONCOLOGY |
| 2005 | The influence of time intervals between loop electrosurgical excision and subsequent hysterectomy on the morbidity of patients with cervical neoplasia | GYNECOLOGIC ONCOLOGY |
| 2021 | The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis | GYNECOLOGIC ONCOLOGY |
| 2016 | Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy | GYNECOLOGIC ONCOLOGY |
| 2016 | Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and U.S. perspectives. | GYNECOLOGIC ONCOLOGY |
| 2021 | Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women | GYNECOLOGIC ONCOLOGY |
| 1998 | Underexpression of Cyclin-Dependent Kinase (CDK) Inhibitors in Cervical Carcinoma | GYNECOLOGIC ONCOLOGY |
| 2022 | Usefulness and potential pitfalls of pre-operative PET-CT in patients with endometrial cancer undergoing one- and two-step sentinel lymph node mapping: Do negative findings on PET-CT negativity really indicate node negativity? | GYNECOLOGIC ONCOLOGY |
